New antibiotics still a decade away unless policymakers, investors step up, AMR Action Fund CEO warns

  13 April 2022

A “broken” investment model means a new antibiotic may not reach the market for another decade, according to the head of a $1 billion Big Pharma-backed fund focused on the growing threat of drug-resistant bacteria.

Urgent market reform is needed to encourage investment and expand the razor-thin pipeline of antibiotics in development, AMR Action Fund CEO Henry Skinner, Ph.D., told Fierce Biotech in an interview. The fund was set up by a who’s who of leading biopharma companies with a mission of bringing up to four new antibiotics to patients by 2030, but even this ambitious goal is just “buying some time,” Skinner said.

Further reading: Fierce Biotech
Author(s): Fierce Biotech
Smart Innovations  


Unrestricted financial support by:


Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre


Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!